Downregulated miR-1247-5p associates with poor prognosis and facilitates tumor cell growth via DVL1/Wnt/β-catenin signaling in breast cancer

Zeng, Beilei; Li, Yunhai; Feng, Yixiao; Lu, Mengqi; Yuan, Hongfan; Yi, Ziying; Wu, Yushen; Xiang, Tingxiu; Li, Hongzhong; Ren, Guosheng

doi:10.1016/j.bbrc.2018.09.103

Cited by 34 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our study, mir-1247-5p could be a novel tumor suppressor and its lower expression was associated with malignant biological behavior and poor prognosis of breast cancer. In latest study, mir-1247-5p was down-regulated in breast cancer [9] and this is in accordance with our conclusion. Although it was a pity that we could not complete the functional assay in this study, we mentioned a variety of pathways which mir-1247-5p might be involved in section of discussion [10][11][12].…”

Section: Commentarysupporting

confidence: 90%

Commentary on “Association of mir12475p Expression with Clinicopathological Parameters and Prognosis in Breast Cancer”

Zhang¹

2018

J Med Surg Pathol

View full text Add to dashboard Cite

Section: Commentarysupporting

confidence: 90%

Commentary on “Association of mir12475p Expression with Clinicopathological Parameters and Prognosis in Breast Cancer”

Zhang¹

2018

J Med Surg Pathol

View full text Add to dashboard Cite

“…For instance, overexpression of miR-153 in prostate cancer can predicate the poor prognosis of patients (35). Downregulation of miR-1247-5p in breast cancer is associated with poor prognosis of patients (36). All the aforementioned findings of the present study, indicate that miR-623 participated in and suppressed the progression of breast cancer.…”

Section: Discussionsupporting

confidence: 63%

“…In addition, all patients participated in a 5-year follow-up survey for the collection of the survival information. Patients were followed-up at 6,9,12,15,18,21,24,30,36,42,48, and 60 months after surgery over the telephone.…”

Section: Methodsmentioning

confidence: 99%

MicroRNA‑623 inhibits tumor progression and is a predictor of poor prognosis of breast cancer

Wang¹,

Wang

Zhang³

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Dysregulated microRNAs (miRNAs) serve vital roles in the progression and prognosis of breast cancer. miR-623 has been reported to influence the progression of numerous other cancers, such as lung adenocarcinoma and hepatocellular carcinoma, however, its role in breast cancer remains unclear. In the present study, the mRNA expression of miR-623 was studied in 121 pairs of breast cancer and adjacent normal tissues and cultured cell lines by reverse-transcription quantitative PCR. The association between miR-623 expression and clinical characteristics or the overall survival rate of patients was investigated by the χ 2 test or Cox regression analysis, respectively. The role of miR-623 in cell proliferation, migration and invasion of breast cancer cells was evaluated by cell transfection to regulate miR-623 expression and the CCK8 and Transwell assays, respectively. miR-623 was downregulated in breast cancer tissues and cell lines compared with normal tissues and breast epithelial cell lines. The χ 2 test demonstrated that the downregulation of miR-623 was associated with the tumor node metastasis (TNM) stage of patients with breast cancer. miR-623 and TNM stage were considered as two independent prognostic factors for breast cancer. Additionally, cell proliferation, migration, and invasion of breast cancer cells were promoted by the downregulation of miR-623, while upregulation of miR-623 led to inhibition of the aforementioned processes. Downregulation of miR-623 in breast cancer is associated with the development of breast cancer and indicates a poor prognosis of patients. The downregulation of miR-623 promotes cell proliferation, migration and invasion of breast cancer. The findings of the present study indicate that miR-623 functions as a prognosis biomarker and a tumor suppressor in breast cancer, which provides a potential therapeutic target for patients with breast cancer.

show abstract

“…In addition, several clinicopathological parameters have been introduced in BC management, including clinical stages, histological grade, histological type and lymph node metastasis (LNM). Nevertheless, some patients that possess the same clinicopathological features have different outcomes of prognosis [ 6 ]. Thus, novel treatment methods for BC are urgently needed.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Long non-coding RNA SATB2-AS1 inhibits microRNA-155-3p to suppress breast cancer cell growth by promoting breast cancer metastasis suppressor 1-like

Cheng

Xia

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background Long noncoding RNAs (lncRNAs) and microRNAs (miRNAs) play vital roles in human cancers. Nevertheless, the effects of lncRNAs and miRNAs on breast cancer (BC) remain to be further investigated. This study was designed to testify the roles of lncRNA antisense transcript of SATB2 protein (SATB2-AS1) and microRNA-155-3p (miR-155-3p) in BC progression. Methods Levels of SATB2-AS1, miR-155-3p and breast cancer metastasis suppressor 1-like (BRMS1L) in BC were determined. The prognostic role of SATB2-AS1 in BC patients was assessed. The screened cells were respectively introduced with altered SATB2-AS1 or miR-155-3p to figure out their roles in malignant phenotypes of BC cells. The effect of varied SATB2-AS1 and miR-155-3p on BC cells in vivo was observed. Dual luciferase reporter gene assay and RNA-pull down assay were implemented to detect the targeting relationship of SATB2-AS1, miR-155-3p, and BRMS1L. Results SATB2-AS1 and BRMS1L were decreased while miR-155-3p was increased in BC cells and tissues. Patients with lower SATB2-AS1 expression had poor prognosis. Elevated SATB2-AS1 and inhibited miR-155-3p were able to restrain malignant behaviors of BC cells in vitro, as well as decelerate tumor growth in vivo. Oppositely, inhibited SATB2-AS1 and amplified miR-155-3p had converse effects on BC cell growth. MiR-155-3p mimic abrogated the impact of overexpressed SATB2-AS1. SATB2-AS1 could sponge miR-155-3p, and BRMS1L was the target gene of miR-155-3p. Conclusion Elevated SATB2-AS1 and inhibited miR-155-3p could suppress the malignant phenotypes of BC cells, thereby restricting the development of BC.

show abstract

Downregulated miR-1247-5p associates with poor prognosis and facilitates tumor cell growth via DVL1/Wnt/β-catenin signaling in breast cancer

Cited by 34 publications

References 26 publications

Commentary on “Association of mir12475p Expression with Clinicopathological Parameters and Prognosis in Breast Cancer”

Commentary on “Association of mir12475p Expression with Clinicopathological Parameters and Prognosis in Breast Cancer”

MicroRNA‑623 inhibits tumor progression and is a predictor of poor prognosis of breast cancer

RETRACTED ARTICLE: Long non-coding RNA SATB2-AS1 inhibits microRNA-155-3p to suppress breast cancer cell growth by promoting breast cancer metastasis suppressor 1-like

Contact Info

Product

Resources

About